Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "leukemia" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-4 z 4
    Tytuł:
    Opposite changes of regulatory T cell blood content may differentially contribute to atherosclerosis or lymphoproliferative disorders
    Autorzy:
    Pylaeva, Ekaterina
    Potekhina, Aleksandra
    Pogorelova, Olga
    Tripoten, Maria
    Balakhonova, Tatiana
    Filatova, Anastasia
    Klesareva, Elena
    Afanasieva, Olga
    Noeva, Elena
    Arefieva, Tatiana
    Powiązania:
    https://bibliotekanauki.pl/articles/1064986.pdf
    Data publikacji:
    2016
    Wydawca:
    Medical Education
    Tematy:
    B-cell chronic lymphocytic leukemia
    Opis:
    Background. Chronic autoimmune inflammation in arterial wall may lead to atherosclerosis progression. Objective. The aim of this study was to investigate the association between Treg, Th17 and B1a cell blood frequencies as well as IgM autoantibodies to oxLDL and the abundance of carotid atherosclerosis. Material and methods. 18 patients with increased IMT (intima-media thickness) and 65 patients with different severity of carotid atherosclerotic plaques were included. Treg, Th17 and B1a cell blood frequencies were assessed via direct immunofluorescence staining and flow cytometry, oxLDL as well as IgM autoantibodies to oxLDL were measured with commercial kits. Results. We observed higher values of Treg in patients without carotid atherosclerosis. Patients with intact carotid arteries as compared to patients with mild atherosclerotic plaques had decreased Th1 levels. OxLDL IgM levels were higher in patients with intact carotid arteries. Patients who received statin treatment had higher levels of Treg. Immunophenotyping of B cells revealed two cases of monoclonal B-cell lymphocytosis and 1 case of B-CLL (B-cell chronic lymphocytic leukemia) in elderly patients with intact carotid arteries. Conclusion. We hypothesize that certain parameters of cell immunity may hamper atherosclerosis while protecting from lymphoproliferative disorders.
    Źródło:
    OncoReview; 2016, 6, 1; A29-36
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Partial remission in patient with Richter syndrome: an „emergency” treatment with pixantrone
    Autorzy:
    Szwedyk, Paweł
    Powiązania:
    https://bibliotekanauki.pl/articles/1035640.pdf
    Data publikacji:
    2020-06-30
    Wydawca:
    Medical Education
    Tematy:
    Richter syndrome
    chemotherapy
    chronic lymphocytic leukemia
    immunotherapy
    pixantrone
    Opis:
    Chronic lymphocytic leukemia is the most commonly recognized type of leukemia in adults. The appearance of systemic symptoms such as weight loss, fever, or local symptoms in the form of rapidly growing organomegaly, lymphadenopathy in a patient with CLL raises the suspicion of transformation into a high-grade lymphoma – defined as Richter syndrome which is usually associated with very poor prognosis. The described case concerns a 71-year-old patient with this diagnosis, in whom due to the confirmed resistance to subsequent lines of immuno- and chemotherapy, an „emergency” treatment with a modern chemotherapy drug from the aza-anthracendion group – pixantrone was used. Treatment with pixantrone was associated with a relatively good response, translating into partial remission (also in the area of infiltrative changes in the head and neck structures), stabilization of the course of the disease and, consequently, allowed to extend the patient’s life.
    Źródło:
    OncoReview; 2020, 10, 2; 52-56
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    The effect of tyrosine kinase inhibitors used in the treatment of chronic myeloid leukemia on the cardiovascular system
    Autorzy:
    Sacha, Tomasz
    Góra-Tybor, Joanna
    Szmit, Sebastian
    Powiązania:
    https://bibliotekanauki.pl/articles/1035757.pdf
    Data publikacji:
    2019
    Wydawca:
    Medical Education
    Tematy:
    cardiovascular toxicity
    chronic myeloid leukemia
    tyrosine kinase inhibitors
    Opis:
    The use of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia has significantly improved the prognosis and outcomes for most patients. Clinical trials indicate that long-term CML therapy requires the introduction of second- or third-generation inhibitors in approximately 40–50% of cases. Effective in the case of imatinib resistance or intolerance, second generation TKI’s can also be used as a first-line treatment, leading to a faster, and deeper molecular response. TKIs, however, have also been observed to cause significant late adverse effects, including cardiovascular complications, which may raise certain safety concerns. The excellent treatment outcomes achieved with tyrosine kinase inhibitors have led to a gradual increase in the number and age of treated patients, and the associated higher incidence and severity of age-related co-morbidities such as diabetes, hypercholesterolemia, atherosclerosis, ischemic heart disease, hypertension, and congestive heart failure, which raise the risk of treatment-related cardiovascular complications. The article discusses the effects of individual TKIs on the pathogenesis of cardiovascular complications and presents the results of clinical trials that studied their impact on the incidence of such events.
    Źródło:
    OncoReview; 2019, 9, 1; 3-21
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Deep molecular response (MR4.5) as a target of therapy with tyrosine kinase inhibitors. MR4.5 – goal of CML treatment
    Autorzy:
    Sacha, Tomasz
    Powiązania:
    https://bibliotekanauki.pl/articles/1065835.pdf
    Data publikacji:
    2014
    Wydawca:
    Medical Education
    Tematy:
    chronic myeloid leukemia
    possibility cure
    therapy targets
    tyrosine kinase inhibitors
    Opis:
    Chronic myeloid leukemia (CML) accounts for 15% of diagnosed leukemias. The annual incidence in two Polish regions has been calculated for 0.7/100,000 of general population. Introduction of tyrosine kinase inhibitors (TKIs) have substantially improved not only the prognosis of CML, but also changed the treatment goals, and the expectations of patients and physicians. The goals of CML therapy include: to prevent the progression towards accelerated phase and blastic phase, to eliminate the risk of death from leukemia, to prolong the length of survival to comparable of healthy population and to attain a quality of life comparable to healthy people. Patients treated up-front with second generation TKIs (2GTKI) have a better chance to achieve faster and deeper response to therapy. Most of patients receiving 2GTKI in first line or e.g. nilotinib after initial phase of imatinib therapy can achieve very deep molecular response (MR4.5), which is a key criterion for discontinuation studies. The results of stop-trials suggest that substantial proportion of patient could achieve sustained treatment-free survival, and that the disease could be controlled despite of persistence of minimal residual disease, which does not require a clinical intervention. Patients group that could benefit most from discontinuation study include younger people, those who have achieved MR4.5 and patients reporting TKI – associated side effects. Achievement of MR4.5 could be considered as a target of CML therapy for considerable proportion of patients. The question of safe TKI dose reduction or therapy cessation should be addressed in the future planned clinical trials.
    Źródło:
    OncoReview; 2014, 4, 1; A27-32
    2450-6125
    Pojawia się w:
    OncoReview
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-4 z 4

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies